Pneumonia is an infection of one or both of the lungs caused by bacteria, viruses, or fungi. It is a serious infection in which the air sacs fill with pus and other liquid. Lobar pneumonia affects one or more sections (lobes) of the lungs. Infants below the age of two years and adults over the age of 65 years are at a higher risk of acquiring pneumonia. Pneumonia vaccine helps in fighting and provides immunization against over 13 types of pneumococcal bacteria known to cause infection in the lungs.
According to World Health Organization, Pneumonia is the single largest infectious cause of death in children worldwide. Pneumonia killed 808 694 children under the age of 5 in 2017, accounting for 15% of all deaths of children under five years old. Pneumonia affects children and families everywhere but is most prevalent in South Asia and sub-Saharan Africa. Therefore, the high prevalence of pneumonia in children worldwide contributes to the growth of the global Pneumonia Vaccines market. Furthermore, the growing old age population along with the increasing incidence of pneumococcal infections, makes the aging population more prone to infections, contributing to the increase in demand for pneumonia vaccines. This factor further escalates the growth of the global Pneumonia Vaccines market.
Additionally, people with a weakened immune system, also people suffering from heart disease, diabetes, smokers, and heavy drinkers, are more likely to get pneumonia. Growth in the population with weakened immune systems contributes to the demand for the pneumonia vaccine. This key factor majorly supports the growth of the global Pneumonia Vaccines market.
Covid-19 Impact on Pneumonia Vaccines Market
In addition, the current Pneumonia Vaccines Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Pneumonia Vaccines Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Pneumonia Vaccines Market Segment Overview
Based on Vaccine Type, the Pneumococcal Conjugate Vaccine segment is the largest contributor to the global Pneumonia Vaccine market and is projected to maintain its dominant position over the stated period. These vaccines can immunize infants and children from 6 weeks to 5 years of age to prevent invasive disease, pneumonia, and acute otitis media. Additionally, the Pneumococcal Polysaccharide Vaccine segment is the fastest-growing segment of the market. This is due to the Pneumovax 23 is proven efficacious against invasive pneumonia disease in healthy young adults. It is mainly indicated to use in the population aged 50 years and above and population aged more than 2 years.
Pneumonia Vaccines Market, By Vaccine Type
· Pneumococcal Conjugate Vaccine
· Pneumococcal Polysaccharide Vaccine
Pneumonia Vaccines Market, By Product Type
· Prevnar 13
· Synflorix
· Pneumovax 23
Pneumonia Vaccines Market, By Sector
· Public
· Private
Pneumonia Vaccines Market, By Distribution Channel
· Distribution Partner Companies
· Non-governmental Organizations (NGO)
· Government Authorities
Pneumonia Vaccines Market Regional Overview
Geographically, North America dominated the global Pneumonia Vaccine market. This is due to the strong presence of leading market players, high prevalence of pneumonia, increasing government focus on immunization programs, and advancements in the administration of vaccines in this region. Europe was the second-largest market for the pneumonia vaccine. Similarly, Asia Pacific is expected to be the fastest-growing market for the pneumonia vaccine. The rising focus of the governments in countries in Asia on enhancing healthcare facilities, government initiatives, increasing disposable income, and rapid economic development contribute to the growth of the Pneumonia Vaccine market in this region.
Pneumonia Vaccines Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Pneumonia Vaccines Market, Key Players
· Glaxosmithkline plc.
· LG Chem Ltd.
· Merck & Co., Inc.
· Panacea Biotec Limited
· Pfizer Inc.
· Pnuvax Incorporated
· Serum Institute of India Pvt. Ltd.
· Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
· SK Bioscience
· Walvax Biotechnology Co., Ltd.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Vaccine Type
- 5.2.1. Pneumococcal Conjugate Vaccine
- 5.2.2. Pneumococcal Polysaccharide Vaccine
- 5.3. Market Analysis, Insights and Forecast – By Product Type
- 5.3.1. Prevnar 13
- 5.3.2. Synflorix
- 5.3.3. Pneumovax 23
- 5.4. Market Analysis, Insights and Forecast – By Sector
- 5.4.1. Public
- 5.4.2. Private
- 5.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.5.1. Distribution Partner Companies
- 5.5.2. Non-governmental Organizations (NGO)
- 5.5.3. Government Authorities
- 5.6. Market Analysis, Insights and Forecast – By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America, Middle East and Africa
6. North America Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Vaccine Type
- 6.2.1. Pneumococcal Conjugate Vaccine
- 6.2.2. Pneumococcal Polysaccharide Vaccine
- 6.3. Market Analysis, Insights and Forecast – By Product Type
- 6.3.1. Prevnar 13
- 6.3.2. Synflorix
- 6.3.3. Pneumovax 23
- 6.4. Market Analysis, Insights and Forecast – By Sector
- 6.4.1. Public
- 6.4.2. Private
- 6.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.5.1. Distribution Partner Companies
- 6.5.2. Non-governmental Organizations (NGO)
- 6.5.3. Government Authorities
- 6.6. Market Analysis, Insights and Forecast – By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Vaccine Type
- 7.2.1. Pneumococcal Conjugate Vaccine
- 7.2.2. Pneumococcal Polysaccharide Vaccine
- 7.3. Market Analysis, Insights and Forecast – By Product Type
- 7.3.1. Prevnar 13
- 7.3.2. Synflorix
- 7.3.3. Pneumovax 23
- 7.4. Market Analysis, Insights and Forecast – By Sector
- 7.4.1. Public
- 7.4.2. Private
- 7.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.5.1. Distribution Partner Companies
- 7.5.2. Non-governmental Organizations (NGO)
- 7.5.3. Government Authorities
- 7.6. Market Analysis, Insights and Forecast – By Country
- 7.6.1. UK
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Russia
- 7.6.7. Rest of Europe
8. Asia Pacific Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Vaccine Type
- 8.2.1. Pneumococcal Conjugate Vaccine
- 8.2.2. Pneumococcal Polysaccharide Vaccine
- 8.3. Market Analysis, Insights and Forecast – By Product Type
- 8.3.1. Prevnar 13
- 8.3.2. Synflorix
- 8.3.3. Pneumovax 23
- 8.4. Market Analysis, Insights and Forecast – By Sector
- 8.4.1. Public
- 8.4.2. Private
- 8.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.5.1. Distribution Partner Companies
- 8.5.2. Non-governmental Organizations (NGO)
- 8.5.3. Government Authorities
- 8.6. Market Analysis, Insights and Forecast – By Country
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. Australia
- 8.6.5. South East Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Vaccine Type
- 9.2.1. Pneumococcal Conjugate Vaccine
- 9.2.2. Pneumococcal Polysaccharide Vaccine
- 9.3. Market Analysis, Insights and Forecast – By Product Type
- 9.3.1. Prevnar 13
- 9.3.2. Synflorix
- 9.3.3. Pneumovax 23
- 9.4. Market Analysis, Insights and Forecast – By Sector
- 9.4.1. Public
- 9.4.2. Private
- 9.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.5.1. Distribution Partner Companies
- 9.5.2. Non-governmental Organizations (NGO)
- 9.5.3. Government Authorities
- 9.6. Market Analysis, Insights and Forecast – By Country
- 9.6.1. Brazil
- 9.6.2. Saudi Arabia
- 9.6.3. UAE
- 9.6.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Glaxosmithkline plc.
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. LG Chem Ltd.
- 10.6. Merck & Co., Inc.
- 10.7. Panacea Biotec Limited
- 10.8. Pfizer Inc.
- 10.9. Pnuvax Incorporated
- 10.10. Serum Institute of India Pvt. Ltd.
- 10.11. Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
- 10.12. SK Bioscience
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
